Severe pneumonia by aciclovir-resistant varicella-zoster virus during etanercept therapy
Authors:
Open Access
- 19 May 2010
- journal article
- case report
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 49 (9) , 1791-1793
Abstract
Sir, Patients treated with antagonists of TNF-α (anti-TNF-α) are at increased risk of bacterial infections [1]. Compared with bacterial infection, little is known about the risk of viral infections in patients undergoing therapy with anti-TNF-α agents. Immunodeficiency is known to trigger the reactivation of varicella-zoster virus (VZV), one of the most common adverse events reported in clinical trials of anti-TNF-α agents [1]. Recent studies observed a mildly increased risk of herpes zoster reactivation in patients treated with anti-TNF-α agents [2–4]. Nevertheless, therapy with the anti-TNF-α agent etanercept was not associated with an enhanced risk of herpes zoster [2, 3].Keywords
This publication has 8 references indexed in Scilit:
- Disseminated Herpes Zoster Mimicking Rheumatoid Vasculitis in a Rheumatoid Arthritis Patient on EtanerceptDermatology, 2009
- Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α AgentsJAMA, 2009
- Herpes zoster in patients taking TNFα antagonists for chronic inflammatory joint diseaseJoint Bone Spine, 2008
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: Associations with prednisone, disease‐modifying antirheumatic drugs, and anti–tumor necrosis factor therapyArthritis & Rheumatism, 2006
- A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older AdultsNew England Journal of Medicine, 2005
- Viral Pneumonia as a Serious Complication of Etanercept TherapyAnnals of Internal Medicine, 2002
- Clinical and Virologic Characterization of Acyclovir‐Resistant Varicella‐Zoster Viruses Isolated from 11 Patients with Acquired Immunodeficiency SyndromeClinical Infectious Diseases, 2001